153 related articles for article (PubMed ID: 27225870)
1. Combination of Rapamycin and Resveratrol for Treatment of Bladder Cancer.
Alayev A; Salamon RS; Schwartz NS; Berman AY; Wiener SL; Holz MK
J Cell Physiol; 2017 Feb; 232(2):436-446. PubMed ID: 27225870
[TBL] [Abstract][Full Text] [Related]
2. Resveratrol potentiates the anti-tumor effects of rapamycin in papillary thyroid cancer: PI3K/AKT/mTOR pathway involved.
Bian P; Hu W; Liu C; Li L
Arch Biochem Biophys; 2020 Aug; 689():108461. PubMed ID: 32531316
[TBL] [Abstract][Full Text] [Related]
3. Resveratrol prevents rapamycin-induced upregulation of autophagy and selectively induces apoptosis in TSC2-deficient cells.
Alayev A; Sun Y; Snyder RB; Berger SM; Yu JJ; Holz MK
Cell Cycle; 2014; 13(3):371-82. PubMed ID: 24304514
[TBL] [Abstract][Full Text] [Related]
4. Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling.
He X; Wang Y; Zhu J; Orloff M; Eng C
Cancer Lett; 2011 Feb; 301(2):168-76. PubMed ID: 21168265
[TBL] [Abstract][Full Text] [Related]
5. Combination of melatonin and rapamycin for head and neck cancer therapy: Suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation.
Shen YQ; Guerra-Librero A; Fernandez-Gil BI; Florido J; García-López S; Martinez-Ruiz L; Mendivil-Perez M; Soto-Mercado V; Acuña-Castroviejo D; Ortega-Arellano H; Carriel V; Diaz-Casado ME; Reiter RJ; Rusanova I; Nieto A; López LC; Escames G
J Pineal Res; 2018 Apr; 64(3):. PubMed ID: 29247557
[TBL] [Abstract][Full Text] [Related]
6. TSC1 involvement in bladder cancer: diverse effects and therapeutic implications.
Guo Y; Chekaluk Y; Zhang J; Du J; Gray NS; Wu CL; Kwiatkowski DJ
J Pathol; 2013 May; 230(1):17-27. PubMed ID: 23401075
[TBL] [Abstract][Full Text] [Related]
7. The combination of rapamycin and resveratrol blocks autophagy and induces apoptosis in breast cancer cells.
Alayev A; Berger SM; Kramer MY; Schwartz NS; Holz MK
J Cell Biochem; 2015 Mar; 116(3):450-7. PubMed ID: 25336146
[TBL] [Abstract][Full Text] [Related]
8. Anti-Breast Cancer Potential of Quercetin via the Akt/AMPK/Mammalian Target of Rapamycin (mTOR) Signaling Cascade.
Rivera Rivera A; Castillo-Pichardo L; Gerena Y; Dharmawardhane S
PLoS One; 2016; 11(6):e0157251. PubMed ID: 27285995
[TBL] [Abstract][Full Text] [Related]
9. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
Sun SY; Rosenberg LM; Wang X; Zhou Z; Yue P; Fu H; Khuri FR
Cancer Res; 2005 Aug; 65(16):7052-8. PubMed ID: 16103051
[TBL] [Abstract][Full Text] [Related]
10. Grape polyphenols inhibit Akt/mammalian target of rapamycin signaling and potentiate the effects of gefitinib in breast cancer.
Castillo-Pichardo L; Dharmawardhane SF
Nutr Cancer; 2012; 64(7):1058-69. PubMed ID: 23061908
[TBL] [Abstract][Full Text] [Related]
11. Combination effects of paclitaxel with signaling inhibitors in endometrial cancer cells.
Xu C; Li X; Li T; Wang X; Yang Y; Xiao L; Shen H
Asian Pac J Cancer Prev; 2011; 12(11):2951-7. PubMed ID: 22393970
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous inhibition of atypical protein kinase‑C and mTOR impedes bladder cancer cell progression.
Patel R; Islam SA; Bommareddy RR; Smalley T; Acevedo-Duncan M
Int J Oncol; 2020 Jun; 56(6):1373-1386. PubMed ID: 32236625
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
14. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
[TBL] [Abstract][Full Text] [Related]
15. In vivo and in vitro effects of RAD001 on bladder cancer.
Vasconcelos-Nóbrega C; Pinto-Leite R; Arantes-Rodrigues R; Ferreira R; Brochado P; Cardoso ML; Palmeira C; Salvador A; Guedes-Teixeira CI; Colaço A; Palomino LF; Lopes C; Santos L; Oliveira PA
Urol Oncol; 2013 Oct; 31(7):1212-21. PubMed ID: 22169072
[TBL] [Abstract][Full Text] [Related]
16. Oleanolic acid suppresses the proliferation of human bladder cancer by Akt/mTOR/S6K and ERK1/2 signaling.
Mu DW; Guo HQ; Zhou GB; Li JY; Su B
Int J Clin Exp Pathol; 2015; 8(11):13864-70. PubMed ID: 26823699
[TBL] [Abstract][Full Text] [Related]
17. Resveratrol as a novel treatment for diseases with mTOR pathway hyperactivation.
Alayev A; Berger SM; Holz MK
Ann N Y Acad Sci; 2015 Aug; 1348(1):116-23. PubMed ID: 26200935
[TBL] [Abstract][Full Text] [Related]
18. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
Peng Y; Li L; Huang M; Duan C; Zhang L; Chen J
Cell Signal; 2014 Dec; 26(12):2782-92. PubMed ID: 25193113
[TBL] [Abstract][Full Text] [Related]
19. CWF-145, a novel synthetic quinolone derivative exerts potent antimitotic activity against human prostate cancer: Rapamycin enhances antimitotic drug-induced apoptosis through the inhibition of Akt/mTOR pathway.
Hung CM; Lin YC; Liu LC; Kuo SC; Ho CT; Way TD
Chem Biol Interact; 2016 Dec; 260():1-12. PubMed ID: 27769712
[TBL] [Abstract][Full Text] [Related]
20. Effects of combining rapamycin and resveratrol on apoptosis and growth of TSC2-deficient xenograft tumors.
Alayev A; Salamon RS; Sun Y; Schwartz NS; Li C; Yu JJ; Holz MK
Am J Respir Cell Mol Biol; 2015 Nov; 53(5):637-46. PubMed ID: 25844891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
